Diflunisal ( DrugBank: Diflunisal )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス6

28. 全身性アミロイドーシス


臨床試験数 : 261 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 177
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000008396
2012/08/0110/07/2012A randomized, double-blind, placebo-controlled trial of diflunisal on familial amyloid polyneuropathy patients of familial amyloid polyneuropathyDiflunisal, 500mg / day, PO, 1 year
Parse, 500mg / day, PO, 1 year
Department of Neurology, Faculty of Life Sciences, Kumamoto UniversityNULLComplete: follow-up complete18years-old65years-oldMale and Female1Phase 3Japan
2EUCTR2006-001066-16-GB
(EUCTR)
25/08/201018/06/2010A randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosisA randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosis Hereditary neuropathic amyloidosis
MedDRA version: 11.;Level: LLT;Classification code 10019889;Term: Hereditary neuropathic amyloidosis
Trade Name: Dolobid
Product Name: diflunisal (dolobid)
INN or Proposed INN: diflunisal
Other descriptive name: 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
John L. BerkNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140United Kingdom;Italy;Sweden
3JPRN-UMIN000001825
2009/04/0131/03/2009Treatment of familial amyloid polyneuropathy (FAP) using diflunisal familial amyloid polyneuropathy (FAP)Orally administration of diflunisalShinshu UniversityNULLComplete: follow-up complete20years-oldNot applicableMale and Female30Not selectedJapan
4EUCTR2006-001066-16-IT
(EUCTR)
30/01/200709/03/2007The effect of diflunisal IND 68092 on familial amyloidosis a randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects. - NDThe effect of diflunisal IND 68092 on familial amyloidosis a randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects. - ND familial amyloidosis
MedDRA version: 9.1;Level: LLT;Classification code 10016202;Term: Familial amyloidosis
Trade Name: DolobidBoston University- The Amyloid Treatment and Research ProgramNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200United Kingdom;Italy;Sweden
5EUCTR2006-001066-16-SE
(EUCTR)
04/01/200709/11/2006The effect of diflunisal (IND 68092) on familial amyloidosis - The Diflunisal TrialThe effect of diflunisal (IND 68092) on familial amyloidosis - The Diflunisal Trial Familial Amyloid Polyneuropathy (FAP)Trade Name: Dolobid
Product Name: diflunisal (dolobid)
INN or Proposed INN: diflunisal
Other descriptive name: 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
John L. Berk, M.D.NULLNot RecruitingFemale: yes
Male: yes
200United Kingdom;Italy;Sweden
6NCT00294671
(ClinicalTrials.gov)
February 200621/2/2006The Effect of Diflunisal on Familial AmyloidosisThe Effect of Diflunisal on Familial AmyloidosisFamilial Amyloid Polyneuropathy;Familial AmyloidosisDrug: diflunisal;Other: placeboBoston UniversityFood and Drug Administration (FDA);National Institute of Neurological Disorders and Stroke (NINDS)Completed18 Years75 YearsAll130Phase 2/Phase 3United States;Italy;Japan;Sweden;United Kingdom;Portugal